ReviewMolecular pharmaceutics2014
Design and applications of bispecific heterodimers: molecular imaging and beyond.
Review in Molecular pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Engineering Bispecific Peptides for Precision Immunotherapy and Beyond.International journal of molecular sciences · 2025Review
- Radiotheranostic landscape: A review of clinical and preclinical development.European journal of nuclear medicine and molecular imaging · 2025Review
- A comparison of [European journal of nuclear medicine and molecular imaging · 2024Article
- Preclinical evaluation of a dual-receptor targeted tracer [European journal of nuclear medicine and molecular imaging · 2023Article
- Radiolabeled NGR-Based Heterodimers for Angiogenesis Imaging: A Review of Preclinical Studies.Cancers · 2023Review
- Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond.European journal of nuclear medicine and molecular imaging · 2022Article
- Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors.PLoS computational biology · 2022Article
- Curcumin loaded sub-30 nm targeting therapeutic lipid nanoparticles for synergistically blocking nasopharyngeal cancer growth and metastasis.Journal of nanobiotechnology · 2021Article
- Development of [European journal of nuclear medicine and molecular imaging · 2021Article
- Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Photo-Click-Facilitated Screening Platform for the Development of Hetero-Bivalent Agents with High Potency.The Journal of organic chemistry · 2020Article
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Evaluation of an Integrin αMolecular pharmaceutics · 2020Article
- PET Imaging of Receptor Tyrosine Kinases in Cancer.Molecular cancer therapeutics · 2018Review
- Multiplexed Targeting of Barrett's Neoplasia with a Heterobivalent Ligand: Imaging Study on Mouse Xenograft in Vivo and Human Specimens ex Vivo.Journal of medicinal chemistry · 2018Article
- Dual-Targeted Molecular Imaging of Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Review
- Clinical Pharmacology and Translational Aspects of Bispecific Antibodies.Clinical and translational science · 2017Review
- ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment.Molecular pharmaceutics · 2017Article
- In Vitro Mouse and Human Serum Stability of a Heterobivalent Dual-Target Probe That Has Strong Affinity to Gastrin-Releasing Peptide and Neuropeptide Y1 Receptors on Tumor Cells.Cancer biotherapy & radiopharmaceuticals · 2017Article
- Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Ligand-based molecular imaging probes have been designed with high affinity and specificity for monitoring biological process and responses. Single-target recognition by traditional probes can limit their applicability for disease detection and therapy because synergistic action between disease mediators and different receptors is often involved in disease progression. Consequently, probes that can recognize multiple targets should demonstrate higher targeting efficacy and specificity than their monospecific peers. This concept has been validated by multiple bispecific heterodimer-based imaging probes that have demonstrated promising results in several animal models. This review summarizes the design strategies for bispecific peptide- and antibody-based heterodimers and their applications in molecular targeting and imaging. The design and application of bispecific heterodimer-conjugated nanomaterials are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.